178910-32-2

Basic information

• Product Name: 3-(2-CHLOROETHOXY)ANILINE
• Synonyms: 3-(2-CHLOROETHOXY)ANILINE;3-(2-chloroethoxy)aniline(SALTDATA: HCl);3-(2-chloroethoxy)benzenamine
• CAS NO: 178910-32-2
• Molecular Formula: C₈H₁₀ClNO
• Molecular Weight: 171.6241
• Mol File: 178910-32-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 305.5 °C at 760 mmHg
• Flash Point: 138.6 °C
• Appearance: /
• Density: 1.195 g/cm³
• Vapor Pressure: 0.000819mmHg at 25°C
• Refractive Index: 1.563
• CAS DataBase Reference: 3-(2-CHLOROETHOXY)ANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-CHLOROETHOXY)ANILINE(178910-32-2)
• EPA Substance Registry System: 3-(2-CHLOROETHOXY)ANILINE(178910-32-2)

Safety Data

• Hazardous Substances Data: 178910-32-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H10ClNO/c9-4-5-11-8-3-1-2-7(10)6-8/h1-3,6H,4-5,10H2

Upstream product

• 87291-34-7 1-(2-chloroethoxy)-3-nitrobenzene 
• 554-84-7 meta-nitrophenol 

Relevant articles and documents

Design, synthesis, and biological study of 4-[(2-nitroimidazole-1h-alkyloxyl)aniline]-quinazolines as EGFR inhibitors exerting cytotoxicities both under normoxia and hypoxia

Purpose: In order to get novel EGFR inhibitors exerting more potency in tumor hypoxia than in normoxia. Methods: A series of 4-[(2-nitroimidazole-1H-alkyloxyl)aniline]-quinazolines were designed and synthesized, and their in vitro cytotoxicity and EGFR inhibitory activity were evaluated. Molecule docking study was performed for the representative compound. Results: The structure-activity relationship (SAR) studies revealed that compounds bearing both meta-chloride and para-(2-nitroimidazole-1H-alkyloxy) groups on the aniline displayed potent inhibitory activities both in enzymatic and cellular levels. The most promising compound 16i potently inhibited EGFR with an IC50 value of 0.12 μM. Meanwhile, it manifested more potent cytotoxicity than the positive control lapatinib under tumor normoxia and hypoxia conditions (IC50 values of 1.59 and 1.09 μM against A549 cells, 2.46 and 1.35 μM against HT-29 cells, respectively). The proposed binding model of 16i in complex with EGFR was displayed by the docking results. Conclusion: This study provides insights for developing hypoxia-activated kinase inhibitors.

2-Pyrimidinyl Pyrazolopyridine ErbB Kinase Inhibitors

The present invention provides 2-pyrimidinyl pyrazolopyridine compounds, compositions containing the same, as well as processes for the preparation and their use as pharmaceutical agents.

PYRROLO[2,3-D]PYRIMIDINES AND THEIR USE

-